All In Biotech

Drug Trial Radar · NCT07288554

A Study of BBT002 in Healthy Volunteers (HVs) and in Patients With Chronic Obstructive Pulmonary Disease (COPD)

A Randomized, Double-Blind, Placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants With Chronic Obstructive Pulmonary Disease (COPD)

Last checked: Nov 19, 2026Latest source record: Jul 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

68

Planned (sponsor's estimate)

Start

Sep 5, 2025

Primary completion

Dec 31, 2026

Study completion May 30, 2027

Sponsor

Lead sponsor
Bambusa TherapeuticsIndustry
Sponsor type
Industry
First posted
Dec 17, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Non randomized
Model
Sequential
Masking
Triple (participant, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study is a randomized, double-Blind, placebo-controlled, Single- and Multiple-ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Immunogenicity, Pharmacodynamics and Clinical Activity of BBT002 in Healthy Volunteers and Participants with Chronic Obstructive Pulmonary Disease (COPD).

Conditions

  • Chronic Obstructive Pulmonary Disease (COPD)

Interventions

  • BBT002Drug

    BBT002 will be administered

  • PlaceboDrug

    Placebo will be administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of participants with adverse events following single and multiple administration of BBT002Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  2. Number of participants with change in Laboratory assessmentsTime frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  3. Number of participants with change in vital sign measurements following dose administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  4. Number of participants with change in physical examination following dose administration.Time frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration
  5. Number of participants with change in 12-lead ECG readingsTime frame: Part A- Up to Day 141; Part B - Up to Day 169 post first dose administration

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • The Second Hospital of Anhui Medical Univesity

    Hefei, Anhui, China · Recruiting

  • The third affiliated hosptial of Guangzhou Medical University

    Guangzhou, Guangdong, China · Recruiting

  • The First Affiliated Hospital of Guangdong Medical University

    Guangzhou, Guangdong, China · Recruiting

  • Jiangmen Central Hospital

    Jiangmen, Guangdong, China · Recruiting

  • Qingyuan People's Hospital

    Qingyuan, Guangdong, China · Recruiting

  • The First People's Hospital of Xinxiang City

    Xinxiang, Henan, China · Recruiting

  • Yichang Central People's Hospital

    Yichang, Hubei, China · Recruiting

  • The Affiliated Hospital of Xuzhou Medical University

    Xuzhou, Jiangsu, China · Recruiting

  • Jiangxi Provincial People's Hospital

    Nanchang, Jiangxi, China · Recruiting

  • Chengdu fifth People's Hospital

    Chengdu, Sichuang, China · Recruiting

  • Zhejiang Provincial People's Hospital

    Hangzhou, Zhejiang, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.